Cargando…

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy

Chemotherapy-induced nausea and vomiting (CINV) is presented in over 30% of cancer patients receiving highly/moderately emetogenic chemotherapy (HEC/MEC). The currently recommended antiemetic therapy is merely based on the emetogenic level of chemotherapy, regardless of patient's individual ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zhihuang, Liang, Wenhua, Yang, Yunpeng, Keefe, Dorothy, Ma, Yuxiang, Zhao, Yuanyuan, Xue, Cong, Huang, Yan, Zhao, Hongyun, Chen, Likun, Chan, Alexandre, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718276/
https://www.ncbi.nlm.nih.gov/pubmed/26765450
http://dx.doi.org/10.1097/MD.0000000000002476
_version_ 1782410769115119616
author Hu, Zhihuang
Liang, Wenhua
Yang, Yunpeng
Keefe, Dorothy
Ma, Yuxiang
Zhao, Yuanyuan
Xue, Cong
Huang, Yan
Zhao, Hongyun
Chen, Likun
Chan, Alexandre
Zhang, Li
author_facet Hu, Zhihuang
Liang, Wenhua
Yang, Yunpeng
Keefe, Dorothy
Ma, Yuxiang
Zhao, Yuanyuan
Xue, Cong
Huang, Yan
Zhao, Hongyun
Chen, Likun
Chan, Alexandre
Zhang, Li
author_sort Hu, Zhihuang
collection PubMed
description Chemotherapy-induced nausea and vomiting (CINV) is presented in over 30% of cancer patients receiving highly/moderately emetogenic chemotherapy (HEC/MEC). The currently recommended antiemetic therapy is merely based on the emetogenic level of chemotherapy, regardless of patient's individual risk factors. It is, therefore, critical to develop an approach for personalized management of CINV in the era of precision medicine. A number of variables were involved in the development of CINV. In the present study, we pooled the data from 2 multi-institutional investigations of CINV due to HEC/MEC treatment in Asian countries. Demographic and clinical variables of 881 patients were prospectively collected as defined previously, and 862 of them had full documentation of variables of interest. The data of 548 patients from Chinese institutions were used to identify variables associated with CINV using multivariate logistic regression model, and then construct a personalized prediction model of nomogram; while the remaining 314 patients out of China (Singapore, South Korea, and Taiwan) entered the external validation set. C-index was used to measure the discrimination ability of the model. The predictors in the final model included sex, age, alcohol consumption, history of vomiting pregnancy, history of motion sickness, body surface area, emetogenicity of chemotherapy, and antiemetic regimens. The C-index was 0.67 (95% CI, 0.62–0.72) for the training set and 0.65 (95% CI, 0.58–0.72) for the validation set. The C-index was higher than that of any single predictor, including the emetogenic level of chemotherapy according to current antiemetic guidelines. Calibration curves showed good agreement between prediction and actual occurrence of CINV. This easy-to-use prediction model was based on chemotherapeutic regimens as well as patient's individual risk factors. The prediction accuracy of CINV occurrence in this nomogram was well validated by an independent data set. It could facilitate the assessment of individual risk, and thus improve the personalized management of CINV.
format Online
Article
Text
id pubmed-4718276
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-47182762016-02-04 Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy Hu, Zhihuang Liang, Wenhua Yang, Yunpeng Keefe, Dorothy Ma, Yuxiang Zhao, Yuanyuan Xue, Cong Huang, Yan Zhao, Hongyun Chen, Likun Chan, Alexandre Zhang, Li Medicine (Baltimore) 5700 Chemotherapy-induced nausea and vomiting (CINV) is presented in over 30% of cancer patients receiving highly/moderately emetogenic chemotherapy (HEC/MEC). The currently recommended antiemetic therapy is merely based on the emetogenic level of chemotherapy, regardless of patient's individual risk factors. It is, therefore, critical to develop an approach for personalized management of CINV in the era of precision medicine. A number of variables were involved in the development of CINV. In the present study, we pooled the data from 2 multi-institutional investigations of CINV due to HEC/MEC treatment in Asian countries. Demographic and clinical variables of 881 patients were prospectively collected as defined previously, and 862 of them had full documentation of variables of interest. The data of 548 patients from Chinese institutions were used to identify variables associated with CINV using multivariate logistic regression model, and then construct a personalized prediction model of nomogram; while the remaining 314 patients out of China (Singapore, South Korea, and Taiwan) entered the external validation set. C-index was used to measure the discrimination ability of the model. The predictors in the final model included sex, age, alcohol consumption, history of vomiting pregnancy, history of motion sickness, body surface area, emetogenicity of chemotherapy, and antiemetic regimens. The C-index was 0.67 (95% CI, 0.62–0.72) for the training set and 0.65 (95% CI, 0.58–0.72) for the validation set. The C-index was higher than that of any single predictor, including the emetogenic level of chemotherapy according to current antiemetic guidelines. Calibration curves showed good agreement between prediction and actual occurrence of CINV. This easy-to-use prediction model was based on chemotherapeutic regimens as well as patient's individual risk factors. The prediction accuracy of CINV occurrence in this nomogram was well validated by an independent data set. It could facilitate the assessment of individual risk, and thus improve the personalized management of CINV. Wolters Kluwer Health 2016-01-15 /pmc/articles/PMC4718276/ /pubmed/26765450 http://dx.doi.org/10.1097/MD.0000000000002476 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial License, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be used commercially. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5700
Hu, Zhihuang
Liang, Wenhua
Yang, Yunpeng
Keefe, Dorothy
Ma, Yuxiang
Zhao, Yuanyuan
Xue, Cong
Huang, Yan
Zhao, Hongyun
Chen, Likun
Chan, Alexandre
Zhang, Li
Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
title Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
title_full Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
title_fullStr Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
title_full_unstemmed Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
title_short Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
title_sort personalized estimate of chemotherapy-induced nausea and vomiting: development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemotherapy
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718276/
https://www.ncbi.nlm.nih.gov/pubmed/26765450
http://dx.doi.org/10.1097/MD.0000000000002476
work_keys_str_mv AT huzhihuang personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT liangwenhua personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT yangyunpeng personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT keefedorothy personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT mayuxiang personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT zhaoyuanyuan personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT xuecong personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT huangyan personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT zhaohongyun personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT chenlikun personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT chanalexandre personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy
AT zhangli personalizedestimateofchemotherapyinducednauseaandvomitingdevelopmentandexternalvalidationofanomogramincancerpatientsreceivinghighlymoderatelyemetogenicchemotherapy